Aspira Women's Health Inc.
aspirawh.comWhat Do They Do?
Sells blood tests that help physicians assess ovarian cancer risk in women with adnexal masses, and develops noninvasive tests for other gynecologic diseases.
10-K for FY2025, filed Apr 1, 2026Aspira Women’s Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the…View ↗
We currently commercialize the following blood test products and related services:View ↗
OvaWatch has been developed and is validated for use in Aspira’s CLIA-certified lab as a non-invasive blood-based risk assessment test for…View ↗
How Do They Make Money?
Aspira bills third-party payers, government health programs, clients and patients for tests. OvaSuite revenue is counted when testing is complete and results reach the physician; collection can take as long as one year.
10-K for FY2025, filed Apr 1, 2026In the United States, revenue for diagnostic tests comes from several sources, including third-party payers such as insurance companies…View ↗
In the United States, our clinical customer base includes physicians, physician office laboratories and national and regional laboratories.…View ↗
Product Revenue – OvaSuite: The Company recognizes product revenue in accordance with the provisions of ASC Topic 606, Revenue from…View ↗
$343K
-
10-K for FY2025, filed Apr 1, 2026
$343K ↗
Who Are Their Customers?
Physicians, physician-office labs, and regional or national labs access tests through direct referrals, Aspira’s platform, or laboratory partners; specimens are sent to Aspira for testing.
10-K for FY2025, filed Apr 1, 2026
Do Revenues Turn Into Profits?
No. It lost $12.8M in FY2025.
10-K for FY2025, filed Apr 1, 2026
−$7.9MView ↗
10-K for FY2025, filed Apr 1, 2026
−$12.8MView ↗
10-K for FY2025, filed Apr 1, 2026
−$7MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$2.4MView ↗
- ▼ −9% (Loss)
- vs −$2.7M in Q2 FY2025
-
Jun 22, 2026
CEO leaves; board chair becomes interim CEO
Michael Buhle ceased serving as CEO, and the board appointed Chairman John Fraser as interim CEO while it searches for a permanent successor.
Sources
8-K, filed Jun 22, 2026
On June 17, 2026, Michael Buhle ceased serving as Chief Executive Officer of Aspira Women's Health Inc. (the "Company"). Effective June 17…View ↗
-
Apr 30, 2026
New CFO and Chief Accounting Officer appointed
John Strahley was appointed CFO and Chief Accounting Officer; Brian Hungerford’s consulting agreement ended.
Sources
8-K, filed Apr 30, 2026
On April 26, 2026, Aspira Women's Health, Inc. (the "Company") appointed John Strahley as Chief Financial Officer and Chief Accounting…View ↗
Repeat OvaWatch testing
The older report presents OvaWatch as an initial assessment, with repeat monitoring still planned; the latest report describes periodic testing at physician-prescribed intervals as part of its current use.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Apr 1, 2026OvaWatch has been developed and is validated for use in Aspira’s CLIA-certified lab as a non-invasive blood-based risk assessment test for…View ↗
In ovarian cancer, we have developed clinical data to support the use of our OvaWatch test multiple times for the monitoring of an adnexal…View ↗
Mayo distribution channel
The latest report adds Mayo Clinical Laboratories as a distribution channel; the older report describes sales through its own sales force, platform and BioReference.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Apr 1, 2026Our Business and Products: We currently market and sell the following products and related services: (1) Ova1, a blood test intended as an…View ↗
Our products are distributed through our direct national sales force, including field sales and inside sales. OvaSuite tests are marketed…View ↗
Who Do They Compete With?
Competes with Fujirebio Diagnostics, AOA Dx, ClearNote Health, Cleo Diagnostics, Mercy BioAnalytics, Exact Sciences, Grail, Afynia, DotLab, Endodiag, HERA Biotech, Heranova, Proteomics International, and Ziwig
10-K for FY2025, filed Apr 1, 2026Fujirebio Diagnostics developed ROMA. ROMA combines two tumor markers and menopausal status into a numerical score using a publicly…View ↗
Loading...
